In the work of Shapira et al., they devised a novel anti‐inflammatory drug, EXO‐CD24, a combination of EVs and immune checkpoint CD24 to improve the prognosis of diseases accompanied by CSS.[131] In a phase Ib/IIa study, 35 patients with a medium to high COVID‐19 severity were recruited and given 108–1010 EXO‐CD24 for 5 d, and no adverse events were observed for 443‐575 d. Here, CD24 is linked to COVID-19.